Pemphigus vulgaris is an intraepidermal autoimmune mucocutaneous blistering disease whose etiopathogenesis includes various trigger factors, i.e., drugs and malignancies. We present a case of malignancy-exacerbated pemphigus vulgaris which required a careful diagnostic process in order to rule out paraneoplastic pemphigus, along with the challenges posed by the need of treating both cutaneous and oncologic diseases. Possible post-operative complications post-poned the start of first-line immunosuppressive treatment of pemphigus. Moreover, the infective risks had to be minimized during the peak of the COVID-19 pandemic in Italy. Intravenous immunoglobulins were chosen as "bridge" therapy before the tumor surgical excision, followed by rituximab in post-operative phase.
Keywords: COVID-19; Ivor Lewis esophagectomy; esophageal cancer; immunoblot; intravenous immunoglobulin; paraneoplastic pemphigus; pemphigus vulgaris; rituximab.
Copyright © 2021 Corrà, Cammelli, Quintarelli, Barbato, Le Rose, Salemme, Di Zenzo, Coratti, Verdelli, Aimo, Mariotti, Bianchi, Cianchi and Caproni.